InvestSMART

Prana Biotechnology Limited (ASX: PBT) - Announcements

Current share price for PBT : $0.049 0.002 (4.26%)+

ASX company news and announcements for Prana Biotechnology Limited (PBT) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Prana Biotechnology Limited (PBT) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Prana Biotechnology Limited (PBT), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Prana Biotechnology Limited (PBT)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Appendix 4C - quarterly 28 Apr 2011 12:22PM $0.180 $0.049 fallen by 72.78%
- Prana accelerates PBT2 commercial development 20 Apr 2011 9:42AM $0.230 $0.049 fallen by 78.70%
- Prana secures key PBT2 patent in Japan 11 Apr 2011 11:36AM $0.230 $0.049 fallen by 78.70%
- Prana`s PBT2 Phase II trial receives funding from ADDF 31 Mar 2011 11:14AM $0.250 $0.049 fallen by 80.40%
- Prana Raises A$6.19 million in a Private Placement 23 Mar 2011 2:10PM $0.265 $0.049 fallen by 81.51%
- PBT2 - Directly Restores Neurons Critical to Cognition 21 Mar 2011 11:39AM $0.165 $0.049 fallen by 70.30%
- Prana`s Co-Founding Scientist Awarded Prestigious Fellowship 4 Mar 2011 9:39AM $0.155 $0.049 fallen by 68.39%
- Half Yearly Report and Accounts 1 Mar 2011 8:36AM $0.180 $0.049 fallen by 72.78%
- Response to ASX Price Query 18 Feb 2011 1:31PM $0.180 $0.049 fallen by 72.78%
- Appendix 4C - quarterly 28 Jan 2011 5:50PM $0.270 $0.049 fallen by 81.85%
- Prana plans to advance Alzheimers clinical trial 8 Nov 2010 1:20PM $0.150 $0.049 fallen by 67.33%
- Trading Halt 4 Nov 2010 6:16PM $0.130 $0.049 fallen by 62.31%
- Appendix 4C - quarterly 27 Oct 2010 5:48PM $0.150 $0.049 fallen by 67.33%
- Prana selects lead PD drug candidate for development 29 Sep 2010 9:55AM $0.130 $0.049 fallen by 62.31%
- Appendix 4E for the Year Ended 30 June 2010 27 Aug 2010 11:24AM $0.130 $0.049 fallen by 62.31%
- Prana secures key PBT2 patents in the US and Europe 24 Aug 2010 9:57AM $0.150 $0.049 fallen by 67.33%
- Appendix 4C - quarterly 30 Jul 2010 4:52PM $0.130 $0.049 fallen by 62.31%
- New PBT2 data in 2010 Hot Topics Session 1 Jul 2010 10:01AM $0.155 $0.049 fallen by 68.39%
- Investment by Quintiles, Placement of 225 million Shares 28 Jun 2010 9:24AM $0.140 $0.049 fallen by 65%
- Appendix 4C - quarterly 30 Apr 2010 3:49PM $0.170 $0.049 fallen by 71.18%
- Prana Provides Analysis of PBT2 Therapeutic Strategy for AD 29 Apr 2010 2:14PM $0.200 $0.049 fallen by 75.50%
- Prana to commence Phase 11b trial on PBT2 20 Apr 2010 2:00PM $0.220 $0.049 fallen by 77.73%
- New Analysis of Clinical Trial published in Journal of AD 19 Apr 2010 10:06AM $0.140 $0.049 fallen by 65%
- Appendix 4D for the Half Year Ended 31 December 2009 25 Feb 2010 4:44PM $0.150 $0.049 fallen by 67.33%
- Appendix 4C - quarterly 29 Jan 2010 4:53PM $0.150 $0.049 fallen by 67.33%

226 - 250 of 331 results

Page 10 of 14

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.